Management of cardiovascular risk in primary prevention: real-world data

被引:0
|
作者
Danchin, N. [1 ]
Puymirat, E. [1 ]
Vedrenne, G. [1 ]
Durand, E. [1 ]
机构
[1] Hop Europeen Georges Pompidou, Dept Cardiol, 20 Rue Leblanc, F-75015 Paris, France
关键词
Primary prevention; Statins; Antihypertensive agents; Tobacco ban; Diabetes; Obesity;
D O I
10.1016/S1878-6480(12)70843-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tremendous progress in the management of cardiovascular risk in the general population has been accomplished over the past two decades, resulting in a decreased incidence of severe cardiovascular conditions such as myocardial infarction, and in a dramatic reduction in cardiovascular mortality. In particular, the management of hypertension and hyperlipidaemia have notably improved. Among public health measures, the smoking ban has been largely successful, while nutritional campaigns and the fight against sedentary behaviours have given mixed results, with continuing growth in the proportion of overweight and obese individuals in the general population. It is therefore essential that recent efforts at prevention are pursued to ensure that the incidence of cardiovascular disease will not rise again in the future. (C) 2012 Elsevier Masson SAS. All rights reserved.
引用
下载
收藏
页码:279 / 283
页数:5
相关论文
共 50 条
  • [11] REAL-WORLD CHARACTERISTICS AND RISK OF CARDIOVASCULAR EVENTS IN HIGH CARDIOVASCULAR RISK PATIENTS IN FRANCE
    Desamericq, G.
    Fagnani, F.
    Emery, C.
    Gourmelen, J.
    Chauny, J. V.
    Kutikova, L.
    ATHEROSCLEROSIS, 2019, 287 : E180 - E180
  • [12] Bleeding and Stroke Risk in a Real-world Prospective Primary Prevention Cohort of Patients With Atrial Fibrillation
    Poli, Daniela
    Testa, Sophie
    Antonucci, Emilia
    Grifoni, Elisa
    Paoletti, Oriana
    Lip, Gregory Y. H.
    CHEST, 2011, 140 (04) : 918 - 924
  • [13] Translating real-world evidence/real-world data
    Ravenstijn, Paulien
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (05):
  • [14] Fracture risk after deprescription of bisphosphonates: Application of real-world data in primary care
    Troncoso-Marino, Amelia
    Vazquez, Marta Leston
    Borge, Sara Gallardo
    Garcia, Jose Luis Del Val
    Guirado, Ester Amado
    Violan, Concepcion
    ATENCION PRIMARIA, 2023, 55 (07):
  • [15] Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-World Population
    Oni-Orisan, Akinyemi
    Haldar, Tanushree
    Cayabyab, Mari A. S.
    Ranatunga, Dilrini K.
    Hoffmann, Thomas J.
    Iribarren, Carlos
    Krauss, Ronald M.
    Risch, Neil
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (05) : 1070 - 1078
  • [16] Cardiovascular safety of insulin: Between real-world data and reality
    Mannucci, Edoardo
    Ferrannini, Ele
    DIABETES OBESITY & METABOLISM, 2017, 19 (09): : 1201 - 1204
  • [17] Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data
    Gavina, Cristina
    Carvalho, Daniel Seabra
    Pardal, Marisa
    Afonso-Silva, Marta
    Grangeia, Diana
    Dinis-Oliveira, Ricardo Jorge
    Araujo, Francisco
    Taveira-Gomes, Tiago
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (22)
  • [18] Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE)
    Mehta, Ashwani
    Jain, Pradeep
    Patil, Ravikant
    Kant, T. Sashi
    Indurkar, Sanjiv A.
    Kota, Sunil Kumar
    Revankar, Santosh
    Gupta, Amit
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (11)
  • [19] REAL-WORLD DATA
    STROCK, JM
    POLICY REVIEW, 1993, 63 : 96 - 96
  • [20] Real-World Data on the Risk of Ventricular Arrhythmias with Sulfonamides
    Gerard, Alexandre O.
    Merino, Diane
    Drici, Milou-Daniel
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (02) : 201 - 202